These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34322382)

  • 1. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.
    Tian Y; Li R; Liu Y; Li M; Song Y; Zheng Y; Gao A; Wen Q; Su G; Sun Y
    Front Oncol; 2021; 11():667650. PubMed ID: 34322382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis.
    Tian Y; Huang A; Yang Y; Dang Q; Wen Q; Wang L; Sun Y
    Front Oncol; 2021; 11():662392. PubMed ID: 34109117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y
    Front Immunol; 2020; 11():595655. PubMed ID: 33391266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
    Liu H; Xu D; Wang W; Sun F; Zhang S; Yang X; Tian Y
    Front Oncol; 2020; 10():570080. PubMed ID: 33194659
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 7. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Deng S; Yang Q; Shu X; Lang J; Lu S
    Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis.
    Tian Y; Zhang C; Dang Q; Wang K; Liu Q; Liu H; Shang H; Zhao J; Xu Y; Wu T; Liu W; Yang X; Safi M
    J Oncol; 2022; 2022():4976032. PubMed ID: 35898927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.
    Wei XC; Guo YY; Zhang Y; Bu YS; Zhang FY
    J Chemother; 2024 Jan; ():1-8. PubMed ID: 38240051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
    Guo X; Li W; Hu J; Zhu EC; Su Q
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
    Zhang C; Zhang S; Xu D; Liu R; Zhu Q; Zhao Y; Mao Y; Tian Y
    Cancer Manag Res; 2019; 11():3957-3969. PubMed ID: 31118808
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
    Ge Y; Zhang H; Weygant N; Yao J
    Front Pharmacol; 2021; 12():640099. PubMed ID: 34447305
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
    Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
    Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis.
    Liu H; Fu L; Jin S; Ye X; Chen Y; Pu S; Xue Y
    Cancer Innov; 2024 Jun; 3(3):e116. PubMed ID: 38947758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
    J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis.
    Hu J; Tian R; Ma Y; Zhen H; Ma X; Su Q; Cao B
    Front Oncol; 2021; 11():645245. PubMed ID: 34123795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
    Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.
    Wu K; Yi M; Qin S; Chu Q; Zheng X; Wu K
    Exp Hematol Oncol; 2019; 8():26. PubMed ID: 31673481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.